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Companion diagnostics (CDx) holds the promise of improving the predictability of the oncol-
ogy drug development process and become an important tool for the oncologist in relation
to the choice of treatment for the individual patient. A number of drug–diagnostic co-
development programs have already been completed successfully, and in the clinic, the
use of several targeted cancer drugs is now guided by a CDx. This central role of the CDx
assays has attracted the attention of the regulators, and especially the US Food and Drug
Administration has been at the forefront in relation to developing regulatory strategies for
CDx and the drug–diagnostic co-development project. For an increasing number of cancer
patients the treatment selection will depend on the result generated by a CDx assay, and
consequently this type of assay has become critical for the care and safety of the patients.
In order to secure that the CDx assays have a high degree of analytical and clinical validity,
they must undergo an extensive non-clinical and clinical testing before release for routine
patient management. This review will give a brief introduction to some of the scientific
and medical challenges related to the CDx development with specific emphasis on the
regulatory requirements in different regions of the world.
Keywords: companion diagnostics, in vitro diagnostics, drug–diagnostic co-development, regulatory requirements,
personalized medicine, precision medicine, oncology
INTRODUCTION
The understanding of the molecular mechanisms of cancer has
increased considerably within the last 10–20 years, which has
resulted in the development of a number of new targeted drugs.
A large proportion of these drugs has been developed using the
drug–diagnostic co-development model where the diagnostic test
and the drug are developed in parallel (1, 2). The use of this model
requires a thorough understanding of the underlying molecular
pathology and the drug mechanisms of action, in order to link
a certain molecular characteristic to the treatment outcome. The
first attempt to use the drug–diagnostic co-development model
was made when trastuzumab (Herceptin®, Roche/Genentech) and
a immunohistochemistry (IHC) assay were developed for HER2
positive advanced breast cancer (3, 4). Since the approval of
trastuzumab and the IHC assay for HER2 overexpression (Her-
cepTest™, Dako) in 1998 by the US Food and Drug Adminis-
tration (FDA), a number of new targeted cancer drugs guided
by a diagnostic assay, a companion diagnostic (CDx) test, has
been approved and introduced in the clinic to the benefit of
the patients (5). The importance of incorporating a CDx in
a drug research project has recently been emphasized by the
fact that approximately two-thirds of the breakthrough therapy
designations granted by the FDA include a diagnostic assay (6).
The main purpose of developing a CDx assay in most oncol-
ogy drug research programs is to have a test that can predict
whether a patient is likely to benefit from the drug in question.
Hence, for many targeted cancer drugs the CDx assays will take
up a central role as a kind of “decisive” stratification factor, both
during development and subsequently after approval when the
drug is used in the clinic. The assay will then become a kind of
“gatekeeper” in relation to the treatment decision (2). However,
if a CDx assay measures a specific biomarker or combination of
biomarkers and it turns out that it is not sufficiently correlated
with the clinical state, which could be overexpression of a spe-
cific protein or genetic mutations, it will not provide meaningful
results. Such an erroneous test result could lead to either a false
positive or false negative result, which potentially may cause risk
and harm to the patient. For example, a false positive result could
lead to treatment with a drug where the biological condition for
a positive outcome is missing, and consequently the patient is
put at risk due to potential toxic side effects from an ineffective
treatment. Similarly, a false negative test result could withhold or
delay a potentially beneficial treatment and thereby also bringing
the patient at risk (7). In oncology, an early and correct diagnosis
and intervention are two elements of key importance in the treat-
ment of cancer patients. In case of a wrong treatment decision,
the disease may become disseminated with no or very low chances
of cure (2).
The central role of CDx assays in relation to both drug develop-
ment and the clinical use after approval has caught the attention
of the regulatory authorities. Especially the FDA has been at
the forefront in relation to developing regulatory strategies for
drug–diagnostic co-development and personalized medicine. As
described above, it is important to avoid false positive and false
negative test results and the analytical and clinical validity of
any CDx assay must be sufficiently documented before it can be
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approved for routine use in the clinic (1, 7). In this article some
of the scientific and medical challenges related to the CDx devel-
opment are discussed with specific emphasis on the regulatory
requirements.
COMPANION DIAGNOSTICS – TERMINOLOGY AND
DEFINITIONS
With regards to the terminology and definitions of a diagnos-
tic assay that is developed in parallel to a targeted drug and
used to guide the treatment decision, there seems to be lack of
consensus. Different names are used in the literature, such as
pharmacodiagnostics, theranostics, pharmacogenomic biomark-
ers, and companion diagnostics. Within the last few years, the
name companion diagnostics has been used more and more fre-
quently and this is also the term that has been adapted by the FDA
and now also the European Union (EU), however, theranostics is
still used quite frequently especially in the academic literature (2).
In 2011, the FDA issued a draft guidance on In vitro Companion
Diagnostics Devices where a CDx was defined (8). According to
this definition a CDx assay is an in vitro diagnostic device that
provides information that is essential for the safe and effective use
of a corresponding therapeutic product. Further, the FDA specifies
three areas where a CDx assay is essential: (1) to identify patients
who are most likely to benefit from a particular therapeutic prod-
uct; (2) to identify patients likely to be at increased risk of serious
adverse reactions as a result of treatment with a particular thera-
peutic product; and (3) to monitor response to treatment for the
purpose of adjusting treatment (e.g., schedule, dose, discontinu-
ation) to achieve improved safety or effectiveness. So according
to the FDA, a CDx assay can be used both to predict outcome
(efficacy and safety) and to monitor the response.
The definition that has been proposed by the EU is somewhat
narrower and is more or less limited to item 1 in the FDA defini-
tion. According to the proposed regulation on in vitro diagnostic
medical devices from 2012, a CDx is a device specifically intended
to select patients with a previously diagnosed condition or pre-
disposition as eligible for a targeted therapy (9). With no doubt
the predictive or selective characteristics of a CDx assay has so far
attracted the most attention. The use of a CDx assay facilitates the
design of clinical trials with a smaller number of subjects, which
has a positive effect on the resources and time spent on clini-
cal development (2). A definition that focuses on the predictive
or selective characteristics of the CDx assay and makes a link to
“personalized medicine” is: “A pre-treatment test performed in
order to determine whether or not a patient is likely to respond to
a given therapy. This type of test is classified as a predictive or selec-
tive test and is a prerequisite for implementation of personalized
and stratified medicine” (10).
DRUG–DIAGNOSTIC CO-DEVELOPMENT
In the drug–diagnostic co-development model there is interde-
pendency of drug and diagnostics. The CDx assay is developed
in parallel to the drug, as illustrated in Figure 1. The success of
such a co-development project depends very much on the strength
of the biomarker hypothesis, which is often deduced during the
early research and preclinical phases of the drug development. As
previously mentioned, it requires a thorough molecular under-
standing of both the pathology and drug mechanisms of action
to come up with a solid hypothesis. It might not only be one
hypothesis which is tested through prototype assays but several
hypotheses. These prototype assays are subsequently used during
the clinical phases I and II in order to give an idea of the predictive
potential.
If one or more of these hypotheses appears promising the assay
will then undergo analytical validation. However, before the ana-
lytical validation of the CDx assay can be finalized, the cut-off
value must be established, which is usually done based on out-
come data from phase I/II clinical trials. During the analytical
validation, it must be demonstrated that the assay accurately and
reliably measures the biomarker that has been selected earlier on
in the development process. In relation to this validation, a num-
ber of both internal and external studies must be performed. For
the external analytical validation a multi-site study is performed to
document reproducibility using the final version of the CDx assay
across several laboratories. Before using the CDx assay for patient
selection and treatment stratification in a clinical phase III trial,
FIGURE 1 |The drug–diagnostic co-development model. The upper parts illustrate the drug development process and the lower parts the parallel CDx
development process with an aligned regulatory co-approval at the end of phase III.
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Table 1 | Overview of the main clinical trial designs that have been proposed for the parallel development of drugs and diagnostics. The last
column in the table lists the diagnostic metrics that can be calculated based on the given clinical trial design. CDx+, test positive patients; CDx−, test
negative patients; PPV, positive predictive value; NPV, negative predictive value.
Clinical trial design Description Diagnostic metrics
All-comers* All patients meeting the study eligibility criteria are enrolled in the trial independent of
the CDx test results
Sensitivity, specificity, PPV, and NPV
Enrichment Only patients who are CDx+ and meet the study eligibility criteria are enrolled in the trial PPV
Stratified Both CDx+ and CDx− patients meeting the study eligibility criteria are enrolled in the
trial and subsequently randomized
Sensitivity, specificity, PPV, and NPV
*Low prevalence of CDx+ patients requires a large sample size.
it is strongly recommended that the assay is analytically validated
(1, 7). Due to challenges with respect to the alignment and timing
of the development of the drug and the CDx assay, it is sometimes
tempting to start the clinical trial with a prototype assay and then
replace it with the validated version later on during the trial. How-
ever, such a strategy is not recommendable as it makes it difficult
to interpret the clinical trial results due to the fact that the patients
have been selected using two different versions of the assay (7). If
different versions of an assay have been used during clinical vali-
dation a subsequent bridging study will be needed, which is both
resource demanding and time consuming. A “golden rule” with
regards to the final clinical validation of a CDx is to use only one
version of the assay, which is the analytically validated version, and
only one testing laboratory in order to reduce possible site to site
variation.
In the drug–diagnostic co-development model, phase III is not
only used to demonstrate safety and efficacy of the drug, but also
to clinically validate the CDx assay. Here, it must be demonstrated
that the CDx assay has an ability to predict the treatment outcome
in the individual patients (7). A CDx assay will only be useful
if it provides information that can discriminate between patients
who are likely responders and non-responders, and in this respect
the clinical diagnostic accuracy of the assay is important, thus
data on the clinical sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) for the CDx assay
are important diagnostic metrics to consider. Several trial designs
for clinical drug–diagnostic co-development have been proposed,
however, not all of them make it possible to calculate the described
diagnostic metrics. Table 1 provides a brief overview of the main
clinical trial designs that have been proposed for the parallel devel-
opment of drug and diagnostic, however, in this article only the
enrichment design will be discussed, as it is the design that so
far has been used most frequently in relation to drug–diagnostic
co-development. Furthermore, a relatively large number of review
articles and draft guidance document have been published within
the last few years describing these trial designs in more details
(1, 2, 11–14).
The enrichment trial design is often used if there is clear evi-
dence of a strong relationship between a positive CDx status and
the treatment outcome with the targeted drug (e.g., from previ-
ous phase I/II studies) (1, 2). With this design, all the patients
are tested by means of a CDx assay, but only the CDx positive
patients are enrolled in the study and subsequently randomized
to either the new targeted drug or to the standard treatment, as
shown in Figure 2. The advantage of this design is that it gen-
erally requires a smaller number of patients to be randomized
compared with the all-comers design, due to the fact that only
patients who have a CDx positive status are enrolled in the trial,
thus making the study population more homogeneous. How-
ever, this design allows only the PPV to be calculated and not
sensitivity, specificity, and NPV, which is a limitation of this a
trial design (1, 2). The enrichment design was also the one used
when trastuzumab went through final phase III testing in women
with advanced breast cancer in the 1990s (3). Further, looking
at the drug–diagnostic combinations that have obtained FDA
approval, the enrichment design is the most frequently used to
demonstrate safety and efficacy of the drug and to clinically val-
idate the corresponding CDx assay. Recent examples of targeted
cancer drugs that have used this trial designs are vemurafenib
(Zelboraf™, Roche/Genentech), crizotinib (Xalkori®, Pfizer), per-
tuzumab (Perjeta®, Roche/Genentech), ado-trastuzumab emtan-
sine (Kadcyla®, Roche/Genentech), dabrafenib (Tafinlar®, GSK),
and trametinib (Mekinist™, GSK). A list of the CDx assays and
their corresponding therapeutic product that have been approved
by the FDA can be found at the webpage of Center for Devices and
Radiological Health (CDRH) (5).
How effective is the use of a CDx in the drug development
process? This question was partly answered in an analysis made
to estimate the risk of clinical trial failure during non-small cell
lung cancer (NSCLC) drug development in the period between
1998 and 2012 (15). The data material was retrieved from differ-
ent available public sources and 676 clinical trials with 199 unique
drug compounds meeting the inclusion criteria of the analysis. The
data showed that the success of clinical phase III was the biggest
obstacle for drug approval with an overall success rate of only 28%.
A small improvement in the success rate was found for the recep-
tor targeted therapies tested in phase III. However, the absolutely
highest success rate was observed when the drug was biomarker-
guided showing a success rate of 62%, as seen in Figure 3. So,
the conclusion from this analysis indicates that the use of a CDx
assay during phase III drug development improves the success rate
considerably. The data from this analysis also seem to confirm the
effectiveness of the enrichment design described earlier in this
paragraph.
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FIGURE 2 |The enrichment clinical trial design. With this design only
patients who have a positive CDx assay result are enrolled in the trial and
randomized (R) to either the new targeted treatment (New) or standard
treatment (Standard). CDx+, indicates test positive patients; CDx−,
indicates test negative patients.
FIGURE 3 | Success rate for NSCLC drugs in phase III clinical trials.
Based on the analysis of 676 clinical trials a success rate of 28% was found
for all types of drugs, however, if the drug was either a receptor target drug
or guided by a CDx assay the success rate increased to 31 and 62%,
respectively (15).
COMPANION DIAGNOSTICS AND REGULATORY
REQUIREMENTS
Recent developments in the field of personalized medicine and
drug–diagnostic co-development have been most challenging, not
only for the regulatory professionals but also for regulatory author-
ities. While drug companies and CDx manufacturers found new
grounds in collaboration to jointly bring their products to patients,
some regulatory authorities have been too slow to adapt to the
changing regulatory landscape caused by the CDx development.
A few highlights of the regulatory process for CDx in the major
markets are presented and discussed below.
FDA SETTING THE STANDARD FOR REGULATORY PATHWAY OF
COMPANION DIAGNOSTICS
In April 2005, the FDA published the Drug–Diagnostic Co-
Development Concept Paper. This document labeled by the FDA
“Draft Preliminary Concept Paper – Not for Implementation”
has become a landmark for the formalization of the drug–
diagnostic co-development strategy (1). Even though the pharma
and diagnostic companies have seldom found the co-development
model for parallel development of drug and diagnostic feasible, it
provided grounds for alternative development strategies and for
obtaining FDA feedback prior to initiating non-clinical or clinical
testing, or prior to intended submission of a marketing applica-
tion. Since 2005, the FDA has taken the lead and set the standard for
the CDx regulatory pathway. This standard also provided inspira-
tion to other authorities and regulatory professionals worldwide.
The FDA further strengthened its leading position in defining the
regulatory landscape for CDx by creating a personalized medicine
group within the Office of In vitro Diagnostics and Radiological
Health (OIR), formerly, Office of In vitro Diagnostics (OIVD) in
2009. This group has contributed to a considerable number of
guidance documents related to CDx. Furthermore, FDA is pro-
viding transparency of the approval process by including web
availability of Safety and Effectiveness Summary documents for
the approved CDx.
While waiting for an update of the 2005 concept paper, a
draft of the In vitro Companion Diagnostic Devices guidance
was published in July 2011 (8). This guidance document is not a
replacement of the 2005 concept paper, but rather an operational
guide for In vitro Diagnostics (IVD) of the pharma and biotech
industries indicating possible regulatory pathways as well as label-
ing and regulatory requirements for CDx devices and therapeutic
products (5).
Attention should be paid to an important section of the guid-
ance covering the investigational use of CDx. Before the “compan-
ion diagnostics era,” many of the investigational IVD devices were
either exempted from Investigational Device Exemption (IDE)
regulations or classified as non-significant risk devices subject to
abbreviated IDE requirements. In the case of clinical trials, where
companion diagnostics are used to make a medical decision –
such as treatment assignment, an IVD is considered a serious risk
device requiring IDE approval by the FDA. Typically, a pharma
or a biotech company is the sponsor of a drug–diagnostic clin-
ical trial conducted under the Investigational New Drug (IND)
regulations. However, it is important that an IDE for the diag-
nostic is either included in the IND or submitted and approved
separately. According to the guidance document, FDA accepts that
the IDE information is included in the IND. However, as the IDE
format is not compatible with an IND, in some cases, the FDA
has expressed that a separate IDE is preferred (16). Hopefully,
this will be further clarified in the final version of the guidance,
which is expected by October 2014 (17). The content of an IDE is
well-defined in the regulations and further specified on the FDA
website and in several guidance documents (18). In the case of a
combined drug–diagnostic clinical trial, the IDE must, in addi-
tion to information on the CDx assay, also include information
provided by the drug sponsor, such as the clinical trial protocol,
investigational sites, Investigational Review Board (IRB) informa-
tion, and informed consent material for patients. Thus, in relation
to collaboration between a drug company and a diagnostic com-
pany, it is important that roles, responsibilities, and timelines are
clearly defined between the parties.
In the 2011 guidance document, the FDA declares that “the
FDA review of the test/therapeutic product pair will be carried
out collaboratively among relevant FDA offices.”Truly, FDA offices
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responsible for each of the products are not only collaborating in
the review process but are also announcing approvals of both the
drug and CDx concurrently.
Another important guidance, not only for CDx, is the Medical
Devices: the Pre-Submission Program and Meetings with FDA
Staff published in draft in July 2012. Final version of the guid-
ance was published in February 2014 (19). In this document, the
Pre-IDE program was renamed to a Pre-Submission (Pre-Sub)
program (19). Since 1995, the Pre-IDE, now Pre-Sub, program,
has allowed industry to obtain FDA feedback prior to any kind of
device submission and thus providing opportunities for the indus-
try to discuss a drug–diagnostic co-development strategy at any
development or testing stage. Even though there is no user fee for
a Pre-Sub, the process has become more formalized since autho-
rization of the Medical Device User Fee and Modernization Act
(MDUFMA) in 2012 (20). In the new guidance, the FDA provides
recommendations to the contents of the Pre-Sub and also clari-
fies the administrative procedures of the program. The Pre-Sub
is a formal, written request for feedback from the FDA regard-
ing analytical or clinical study protocols or a proposed regulatory
pathway. A Pre-Sub may also be an appropriate way to acquaint
the FDA with a novel technology or design. A Pre-Sub interac-
tion with the FDA is a particularly useful way to discuss testing
strategies which are not the ideal co-development scenarios, and
where an analytically validated assay is not available at an early
stage of the clinical drug development. The benefits of Pre-Subs
may include time and cost reduction of research or clinical studies,
better understanding of FDA expectations and trends, especially
in the area where no guidance documents are available, and, most
importantly, may result in a better and more complete market-
ing application and greater chance of a successful approval. In
order to improve the understanding of IVD related issues, it is
recommended that the drug sponsor participates in the Pre-Sub
process initiated by the diagnostic company. If relevant, CDRH
will request Center for Drug Evaluation and Research (CDER)
attendance in the process. According to the FDA statistics, the
inter-center consultations have increased from 39 in 2010 to 106
in 2012 (16), which is a likely consequence of the increased num-
ber of drug–diagnostic co-development projects mainly within
oncology.
The controls required by the FDA prior to marketing of a
device in the US depend on the classification of the device. Med-
ical devices, including IVDs, are risk-classified as class I, II, or III.
The majority of companion diagnostic IVDs are high risk class
III devices. This review will not go into details of the regulatory
requirements for each product class, but only give a very brief
summary. For class I devices, general controls, like establishment
registration and device listing, apply; for class II devices, general
controls and a premarket clearance [510(k)] is needed; and class
III devices require the most stringent approval for medical devices
by the FDA, a Premarket Approval Application (PMA) (21).
Briefly, a PMA application may be either traditional or mod-
ular. There is no difference in the contents of a traditional or a
modular PMA but there is a difference in the way the PMA is
submitted for FDA review. In a traditional PMA, all information
required by the regulations is submitted at the same time, while for
a modular PMA the information is submitted in modules. Thus,
analytical performance (non-clinical studies) and manufacturing
information may be submitted and reviewed by the FDA while a
clinical trial is ongoing. When the clinical trial is completed, the
data will then be submitted to the FDA. At this point of time, the
other modules have been through FDA review. This approach may
allow for a shorter approval process and a better alignment with
the drug approval.
A modification in an intended use for a PMA-approved CDx,
such as adding a new indication or a new targeted drug, is a
complex process which, depending on the type of modification,
may require massive analytical and/or clinical data. The FDA is
very responsive to Pre-Subs for device modifications and provides
feedback to proposed regulatory pathways and studies supporting
regulatory submission for the change in the intended use of the
specific CDx.
EUROPE TIGHTENS UP THE IVD LEGISLATION
The IVD Directive 98/79/EC regulates in vitro diagnostic medical
devices in the EU, EU candidate countries, and associated coun-
tries (22). The current EU regulatory framework for IVD devices
demonstrates how unnoticed CDx IVD devices were at the end
of the nineties when the IVD Directive was proposed and subse-
quently entered into force in 2003. There is no specific mention
of CDx in the definition of an IVD, and the classification system
of the directive does not consider CDx at all. Also, the IVD Direc-
tive list-based classification system has shown its limitations, as
only a limited number of IVD devices are considered medium or
high risk devices (so-called Annex II devices). All remaining IVDs,
including CDx assays, are classified as low risk devices. Adding a
new device to the Annex II list has proved to be a cumbersome
process. It has taken 4 years to add a variant Creutzfeldt–Jakob
disease assay to List A of Annex II, which the United Kingdom
requested in 2007, and the decision from the EU Commission
came only in 2011 (23).
Briefly, IVD devices placed in the EU market require a CE-mark
to indicate conformity with the IVD Directive. For the high risk
products listed in Annex II, the involvement of a Notified Body
(NB) is required to assess conformity to the IVD Directive before
placing the device in the European market. An NB is an organi-
zation accredited by a member state to assess the manufacturer’s
conformity to the essential requirements of the directive.
Currently, any CDx assay entering the EU market is classi-
fied as low risk device based on a conformity assessment and
CE-marking by the manufacturer, the so-called self-certification
procedure. This results in incomprehensible differences in the reg-
ulatory pathway to the market between the USA (PMA approval)
and the EU (self-certification).
However, there are major changes under way in EU IVD medical
device legislation, which will impact CDx assays entering the mar-
ket. The IVD Directive will be replaced by a Regulation on IVD
(9). A regulation is the most powerful, single regulatory frame-
work, which is applicable in a uniform manner at the same time
for all EU member states, which leaves no room for divergent
transpositions.
A draft of the new IVD Regulation (IVDR) has already been
proposed, and obviously, we will be facing a very different reg-
ulatory landscape in the EU in the years to come (9). In the
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classification system proposed in the IVDR, IVDs will be assigned
to four classification groups A, B, C, and D, depending on device
risk, with class A being the lowest risk class. The four-class system
resembles what we already know from the Canadian and Australian
regulations, and is similar, but not equal, to what has been pro-
posed by a Global Harmonization Task Force (24). CDx assays will
be Class C devices and will require a complex regulatory pathway
including a requirement for a Design Examination Certification
by an NB. The review by the NB may possibly also be linked to
a consultation with the European Medicines Agency (EMA) or,
alternatively, compliance to a Common Technical Specifications
(CTS) will be required. The CTS for new devices will be drafted as
part of the review process. No matter which of the proposed path-
ways (EMA consultation or CTS) becomes final, the time to the
market for a CDx assay will be extended essentially. It is assumed
that the proposed IVDR will pass through the Council and Par-
liament in 2014, and the Regulation will then enter into force in
2017, after a 3-year implementation period.
JAPAN EXPECTED TO MIRROR FDA REVIEW AND APPROVAL PROCESS
In Japan CDx assays are classified as high risk devices (class
III), however, the regulatory approval process has until now been
disconnected from the approval of the related therapeutic prod-
ucts. In October 2011, the Japan Association of Clinical Reagent
Industries (JACRI) addressed the Ministry of Health, Labour and
Welfare (MHLW) and the Pharmaceuticals and Medical Devices
Agency (PMDA) with a proposal for a regulatory pathway for
companion diagnostics (25). At the end of December 2013, the
final guidance for CDx and related drugs was announced in the
PMDA Notification. The guidance includes a CDx device defini-
tion, guidance for application for CDx and therapeutic products,
clinical studies of therapeutic products as well as a review system by
PMDA. In the original proposal presented to the MHLW/PMDA,
JACRI has taken into consideration the FDA draft guidance on
In vitro Companion Diagnostic Devices that was issued in July
2011 (8). Thus, the final PMDA guidance stresses that application
for both a CDx and its corresponding therapeutic product should
be submitted and reviewed at the same time under PMDA. Fur-
thermore, it is recommended that drug and diagnostic sponsors
seek early consultation with the authorities on the regulatory path-
way for CDx, similar to the FDA Pre-Sub program. It is expected
that publication of the guidance will improve the review process
for companion diagnostics IVDs in Japan and make it more trans-
parent. There is no English version of the guidance available at the
moment on the PMDA website (26).
CHINA REGULATORY PATHWAY IS A CHALLENGE
Requirements for registration of IVD devices in China exceed
requirements in any of the other countries and regions described
above. Here, CDx assays are as in the US and Japan, classified
as high risk devices (class III products). So far, there have been
no guidance documents issued for CDx assays, but the registra-
tion process follows the requirements for class III products and
requires extensive documentation and supporting testing data to
be submitted to the China Food and Drug Administration. Specific
for a class III IVD device in China, there is a requirement for local
testing of at least 1000 patient specimens divided among three
geographically distinct hospitals. This testing must be performed
using three consecutive lots of the device and further detailed lot
records, including specific requirements for stability testing and
analytical performance testing must be provided. In addition, a
number of legal documents are required to be submitted such as
legal qualification of the manufacturer and authorization letters
for authorized representatives.
CONCLUSION AND FUTURE CONSIDERATIONS
Companion diagnostics holds the promise of improving the pre-
dictability of the oncology drug development process and become
an important tool for the oncologist in relation to the choice of
treatment for the individual patient. A number of drug–diagnostic
co-development projects have already been completed successfully,
and in the clinic, the use of several targeted cancer drugs are now
guided by a CDx. For these drugs the management of the patient
partly depends on the result generated by the CDx assay, and con-
sequently this type of assay has become critical for the patient care.
In order to avoid “false positive” and “false negative” test results, it
must be documented for any CDx assay that it has a high degree
of analytical and clinical validity (7). To some extent this is com-
parable to the safety and efficacy documentation that needs to be
generated in order to achieve a marketing authorization for a new
drug (27).
The central role of the CDx assays in relation to the current
and future pharmacotherapy has attracted the attention of the
regulators, especially the US FDA. In the US, CDx assays are in
most cases classified as class III, high risk devices, for which the
most stringent requirement for safety and effectiveness documen-
tation apply, including submission of a PMA. Knowing the critical
role of a CDx assay in relation to patient management this seems
only reasonable that a number of other countries including Aus-
tralia, Canada, China, and Japan have followed suit with regards
to stringent requirements. However, for the EU, it has taken some
time to realize the critical importance of CDx assays in relation
to patient care and safety, and only recently the discussions about
a more up to date regulation for IVD medical devices including
CDx assay has started. Despite the coming new legislation in the
EU not seeming to have the same formalized co-development and
co-approval process as in the US, it will most likely increase the
patient safety.
Many of the biological characteristics important for a spe-
cific drug to be effective, such as mutations, gene rearrangements,
gene amplifications, and protein overexpression are typically not
present in one cancer type alone, but are often found across several
cancer diseases. HER2 amplification and protein overexpression
are such examples, where these characteristics are found in breast
and gastric cancer as well as others cancers. Further, it has also been
shown that an HER2 targeted drug like trastuzumab is effective
in both breast and gastric cancer (3, 28). This and other exam-
ples have shown what matters most in relation to determining
the response to a specific drug is the molecular pathways driving
the growth of the cancer and not from where in the body the
tumor originates. Based on this knowledge, we will probably see
drug–diagnostic combination being developed for several cancer
diseases simultaneously in the future, which will be both scientifi-
cally and medically challenging. How the drug regulatory system,
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such as the FDA, will handle this challenge will also be interesting
to see, as both drugs and CDxs have been approved for one cancer
disease at a time up to now.
Most of the CDx guided targeted cancer drugs that have been
introduced within the last few years have shown significantly high
response rates and prolonged progression free survival in specific
selected groups of patients. Previously, for many of the treated
patients no treatment has been available for their specific disease,
and CDx guided drugs definitively represent a real progress within
oncology. However, for all these drugs, resistance will develop at
some point in time resulting in disease progression. For this reason
it is unlikely that“monotherapy”with a targeted cancer drug based
on identification of a single biomarker will achieve long-lasting
remission, and we will probably need to move away from the “one
biomarker one drug” model toward a more multimodal approach
(29). This new model will need to integrate multiple biomark-
ers and multiple targeted cancer drugs and should be based on a
simultaneous use of several drugs in order to block more signal
pathways, thus to prevent resistance to develop. When it comes to
CDx assays, this will make a call on specifically designed multiplex
assays most likely based on technologies such as gene expression
arrays or next generation sequencing (NGS) (30). Despite the very
recent decision by the FDA to grant marketing authorization for
the Illumina instrument platform for screening and diagnosis of
cystic fibrosis, there still seems to be a number of challenges that
must be overcome before we see NGS as CDx for targeted cancer
drugs (31, 32). However, the advantages of this type of technology
are that they will enable researchers and healthcare professionals
to get a broader look at the cancer patients’ genetic makeup and
probably help them designing more effective treatment modalities.
Several CDx possibilities seem to be available to improve the treat-
ment of the cancer patients, however, the development of assays
will face a challenging time both with respect to medical/scientific
as well as regulatory aspects.
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